Should I buy or sell Alpine Immune Sciences stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares. View ALPN analyst ratings or view top-rated stocks .

What is Alpine Immune Sciences' stock price target for 2024?

11 brokers have issued 1 year price targets for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $65.00. On average, they expect the company's share price to reach $50.33 in the next twelve months. This suggests that the stock has a possible downside of 22.0%. View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts .

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 at the beginning of 2024. Since then, ALPN shares have increased by 238.7% and is now trading at $64.55. View the best growth stocks for 2024 here .

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 5,280,000 shares, a decrease of 5.9% from the March 15th total of 5,610,000 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 4.4 days. View Alpine Immune Sciences' Short Interest .

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALPN earnings forecast .

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its earnings results on Monday, March, 18th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.32) by $0.47. The biotechnology company earned $30.85 million during the quarter, compared to analysts' expectations of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%.

What ETFs hold Alpine Immune Sciences' stock?

ETFs with the largest weight of Alpine Immune Sciences (NASDAQ:ALPN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) , ALPS Medical Breakthroughs ETF (SBIO) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , Invesco DWA SmallCap Momentum ETF (DWAS) , Principal Healthcare Innovators ETF (BTEC) and AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) .

What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , Abeona Therapeutics (ABEO) , CymaBay Therapeutics (CBAY) , Genocea Biosciences (GNCA) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Energy Transfer (ET) and Palatin Technologies (PTN) .

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Banque Cantonale Vaudoise (0.03%), Mesirow Financial Investment Management Inc. (0.02%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold , Orbimed Advisors Llc, Peter A Thompson and Robert E Conway . View institutional ownership trends .

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free ALPN Stock Alerts

$64.55

+0.12 (+0.19%)

(As of 04/19/2024 ET)

Compare

Today's Range: $64.40
▼
$64.55
50-Day Range: $28.77
▼
$64.55
52-Week Range: $6.71
▼
$64.57

Volume: 3.98 million shs
Average Volume: 3.88 million shs
Market Capitalization: $4.23 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.33

Get Alpine Immune Sciences alerts:

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.27 Rating Score
Upside/Downside: 22.0% Downside
$50.33 Price Target
Short Interest: Healthy
8.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.83
Based on 18 Articles This Week
Insider Trading: Selling Shares
$5,192 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.74) to ($1.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

Medical Sector

687th out of 911 stocks

Pharmaceutical Preparations Industry

309th out of 418 stocks

2.1

Analyst's Opinion

Consensus Rating
Alpine Immune Sciences has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Alpine Immune Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
8.05% of the outstanding shares of Alpine Immune Sciences have been sold short.
Short Interest Ratio / Days to Cover
Alpine Immune Sciences has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Alpine Immune Sciences has recently decreased by 5.88%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alpine Immune Sciences does not currently pay a dividend.
Dividend Growth
Alpine Immune Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALPN.

3.2

News and Social Media Coverage

News Sentiment
Alpine Immune Sciences has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Alpine Immune Sciences this week, compared to 3 articles on an average week.
Search Interest
36 people have searched for ALPN on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alpine Immune Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,192.00 in company stock.
Percentage Held by Insiders
42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.74) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alpine Immune Sciences is -100.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alpine Immune Sciences is -100.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alpine Immune Sciences has a P/B Ratio of 11.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALPN Stock News Headlines

April 18, 2024 | msn.com

TD Cowen Downgrades Alpine Immune Sciences (ALPN)

April 17, 2024 | prnewswire.com

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 17, 2024 | msn.com

Alpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24

April 17, 2024 | americanbankingnews.com

Alpine Immune Sciences (NASDAQ:ALPN) Receives Hold Rating from TD Cowen

April 17, 2024 | americanbankingnews.com

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update

April 15, 2024 | investorplace.com

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

April 15, 2024 | americanbankingnews.com

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) to Post Q1 2024 Earnings of ($0.45) Per Share, Wedbush Forecasts

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 14, 2024 | americanbankingnews.com

Alpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading Volume

April 14, 2024 | americanbankingnews.com

Alpine Immune Sciences (NASDAQ:ALPN) Cut to "Market Perform" at Leerink Partnrs

April 14, 2024 | americanbankingnews.com

SVB Leerink Downgrades Alpine Immune Sciences (NASDAQ:ALPN) to Market Perform